

Original Research Article

 Received
 : 18/11/2024

 Received in revised form
 : 04/01/2025

 Accepted
 : 20/01/2025

Keywords: COPD, mMRC, 6MWT, ICS therapy, 25(OH) vit. D.

Corresponding Author: **Dr. Musku Manasa,** Email: dr.aruna.rajendran@gmail.com

DOI: 10.47009/jamp.2025.7.1.45

Source of Support: Nil, Conflict of Interest: None declared

Int J Acad Med Pharm 2025; 7 (1); 228-231



STUDY OF VITAMIN D STATUS IN COPD PATIENTS OF TELANGANA

V. Gopi Krishna¹, Kairi Anil², K. Bhanu Priya³, Musku Manasa⁴

Assistant Professor, Department of Respiratory Medicine, Gandhi Medical College Secunderabad, Telangana, India.

²Assistant Professor, Department of Respiratory Medicine, Government Medical College, Mulugu, Telangana, India.

³Assistant Professor, Department of Respiratory Medicine, Gandhi Medical College, Secunderabad, Telangana, India.

⁴Assistant Professor, Department of Respiratory Medicine, Gandhi Medical College, Secunderabad, Telangana, India.

Abstract

Background: Vitamin D levels play a significant role in maintaining the pathophysiology of the lungs. Its deficiency causes chronic lung diseases like COPD, ILD, asthma, etc. The present study aimed to evaluate the status of vitamin D in patients suffering with COPD and its severity. **Materials and Methods:** A total of 300 (three hundred) COPD patients were studied. A detailed clinical history and examination were done. Dyspnea was graded according to mMRC. BMI, 6-MWT, CXR, ECG, spirometry, and laboratory tests for 25 (OH) vitamin D were carried out to correlate the severity of COPD and vitamin D levels. **Results:** The mean values of the mMRC dyspnea scale, 6-minute walk test, and FEV1% were 2.55 (\pm 0.47), 228.94 (\pm 149.58), and 50.86 (\pm 16.28), respectively. The mean value of vitamin D level at different age groups, according to mMRC dyspnea scale, 6 MWT, and ICS therapy, had significant p-values (p < 0.001). **Conclusion:** In this study we observed a strong relationship of low vitamin D levels with increased COPD severity and age.

INTRODUCTION

Chronic obstructive pulmonary disease and chronic respiratory diseases are common causes of mortality and morbidity globally, with impairment of quality of life and costs of living.^[1] It is observed that attenuating and ameliorating the frequency and severity of COPD varies with the status of vitamin D levels.

Vitamin D (25-OH) is capable of tissue remodeling of lungs, reduction of pro-inflammatory cytokines, and beneficial modulation of both innate and adaptive immune systems.^[2] It regulates more than 1000 genes and is critical for normal human physiology beyond the skeletal system.^[3]

Vitamin D deficiency is present in 40%-70% of COPD patients and is of particular interest due to the potential effects of vitamin D on muscle strength and physical performance, as well as exacerbations and lung function decline. Low 25-OH-vitamin D levels are associated with poor lung function and COPD exacerbation outcomes.^[4] Therefore, there is a need to assess the vitamin D status and severity in COPD patients across various age groups.

MATERIALS AND METHODS

A multicentric cross-sectional observation study was conducted among various OPDs in Telangana. 300 (three hundred) diagnosed COPD patients aged between 40-85 years were studied.

Inclusion Criteria: Patients diagnosed with COPD in the age group between 40-85 years with informed consent in writing were selected.

Exclusion Criteria: Patients with lung diseases other than COPD, other systemic diseases (nutritional deficiency, anemia), etc., were excluded from the study.

Method: Every patient's clinical history, dyspnea scale (mMRC), and smoking history were determined as current smoker, ex-smoker, and never smoker; socio-economic status and usage of inhaled corticosteroids were recorded; physical examination, 6-MWT, BMI, CXR, ECG, spirometry, and laboratory tests for 25 (OH) vitamin D were carried out.

Serum 25 (OH) vitamin D level was measured by a fully automated antibody-based chemiluminescence (CLIA) assay; serum 25 (OH) vitamin D level was the best marker of body vitamin D status. Spirometry was carried out using the Schiller sensor SP-260. Tests were performed in a sitting position before and

228

15 minutes after 400 mcg salbutamol was given via nebulizer with a nose clip. Three to four trials were given. Best of all, trials were included where expiration continued for > 6 seconds with an acceptable flow volume loop. FEV1 and FEV1/FVC parameters were used to diagnose COPD, where FEV1% predicted were used in the study for severity of COPD.

Duration of study was from November 2023 to December 2024.

Statistical Analysis: Various characteristic features of patients, comparison of Vit. D levels, various age groups, grades of mMRC dyspnea, mean values of 6MWT, and users and non-users of ICS therapy were studied with ANOVA tests and t-tests. The statistical analysis was carried out using SPSS software.

RESULTS

Table 1: Characteristic features of patients with COPD

- Total numbers of patients are 300: 27.84 (± 11.45) mean value of vit. D ng/ml, 2.55 (± 0.47) mean value of mMRC dyspnea. In the 6-minute walk test, the mean value was 50.80 (± 16.2).
- FEV1% predicted mean value was 50.86 (± 16.28), with 98 (32.6%) smokers, 168 (56%) exsmokers, and 34 (11.3%) non-smokers. COPD status: 14 (8%) mild, 97 (32.3%) moderate, 130 (43.3%) severe, and 49 (16.3%) very severe.

 Table 2: Mean serum 25(OH) vitamin D levels in different age groups

- In 40-59 years: 77 patients had a mean value of vit D of 31.04 (±17.02).
- In 60-69 years of age, 130 patients had a mean value of vit D of 31.28 (± 16.36).
- In 70-79 years of age, 19.90 (± 11.76) was the mean value of vitamin D.
- In > 80 years, 26 patients had a mean value of vit. D of 23.12 (± 10.30). ANOVA F value was 2.21 and p < 0.001 (p value was highly significant).

Table 3: Mean value of vitamin D according toMRC dyspnea grade among COPD

- In grade I of mMRC Dyspnea: 36 patients had a mean value of vitamin D of 54 (± 11.65).
- In grade II: 87 patients 87 patients had 36.90 (±10.7) mean value of vit D.
- In grade III: 105 patients, 24.8 (± 9.4) was the mean value of vit. D.
- I grade-IV: 72 patients had 14.16 (± 6.02), which was the mean value of vit. D. F value was 172.5, and p < 0.001.

Table 4: Comparison of mean value of vitamin Dlevels according to the 6-minute walk test amongCOPD patients

- 400 meters had 52 patients, and their mean value of vitamin D was 48.72 (± 9.08).
- 399-300 meters had 45 patients; their mean value of vit. D was 39.08 (± 8.30).

- 299-200 meters had 109 patients; their mean value of vit. D was 20.19 (±4.08).
- In < 99 meters, there were 62 patients; their mean value of vit. D was 11.09 (± 4.80). The F value was 290.7, and p < 0.001.

Table 5: Comparative study of inhaled corticosteroid therapy among COPD patients—156 patients were using ICS therapy, and 144 were not using ICS therapy. The mean value of vitamin D users of ICS was $21.45 (\pm 4.15)$, and the mean value of vitamin D in non-users was $34.63 (\pm 8.3)$. The t-test was 17.2, and p < 0.001 (the p-value was highly significant).




 Table 1: Characteristic features of the patients with
 COPD




Table 2: Comparison Mean serum 25 (OH) vitamin Dlevels in different age groups




 Table 3: Comparison means vitamin D level according to mMRC Dyspnea grades among COPD




 Table 4: Comparison of mean values of vitamin D levels

 according to 6 minutes walk test among COPD




Table 5: Comparison of Inhaled corticosteroid (ICS)therapy among COPD

Cable 1: Characteristic features of the patients with COPD			
Characteristic	Mean or Number		
Total number	300		
Vitamin D level mean ng/m	27.84 (± 11.45)		
mMRC dyspnea (mean)	2.55 (± 0.47)		
6 minutes' walk test (metre)	228.94 (± 149.58)		
FEV1% predicted	50.86 (± 16.28)		
Smoking status			
1. Current smoker	98 (32.6%)		
2. Ex-smoker	168 (56%)		
3. Non-smoker	34 (11.3%)		
COPD Status Mild	24 (8%)		
Moderate	97 (32.3%)		
Severe	130 (43.3%)		
Very severe	49 (16.3%)		

Table 2: Comparison Mean serum 25 (OH) vitamin D levels in different age groups

Age groups (years)	Number of patients	Mean (±SD)	t test F value	p value
40-59 years	77	31.04 (±17.82)	2.213	P<0.001
60-69 years	130	31.28 (±16.36)		
70-79 years	67	19.90 (±11.76)		
> 80 years	26	23.72 (±10.50)		

(p<0.001 = p value is highly significant)

Comparison means vitamin D level according to mMRC Dyspnea grades among COPD				
mMRC Dyspnea	Number of patients	Vit. D level ng/ml	ANOVA F	p value
Grade – I	36	54 (±11.65)	172.5	P<0.001
Grade – II	87	36.90 (±10.7)		
Grade – III	105	24.30 (±9.1)		
Grade – IV	72	14.16 (±6.02)		
	f_{accent} (m < 0.001)			

p value is highly significant (p<0.001)

Table 4: Comparison of mean values of vitamin D levels according to 6 minutes walk test among COPD				
6 minute walk test 6 (MWT)	Number of patients	Vit. D level ng/ml (Mean ±SD)	ANOVA F value	p value
> 400 metre	52	48.72 (±9.08)	290.7	P<0.001
399-300 metre	45	39.08 (±18.30)		
299-200 metre	32	30-00 (±7.20)		
199-100 metre	109	20.19 (±5.23)		
< 99 metre	62	11.09 (±4.80)		

Table 5: Comparison of Inhaled corticosteroid (ICS) therapy among COPD

ICS Therapy	Number of patients	Vit. D level ng/ml (Mean ±SD)	t test	p value
Yes	156	21.45 (±4.15)	17.2	P<0.001
No	144	34.63 (±8.5)		

DISCUSSION

The characteristic features of patients vitamin D mean level were 27.84 (\pm 11.45), the mMRC mean value was 2.55 (\pm 0.47), and the 6 MWT test meter mean value was 228.9 (± 149.5). Mean value of FEV1 predicted: 50.86 (± 16.7) 98 (32.6%) current smokers, 168 (56%) ex-smokers, and 34 (11.3%) non-smokers; COPD status: 24 (8%) mild, 97 (32.3%) moderate, 130 (43.3%) severe, and 49 (16.3%) very severe (Table 1). Comparison of mean severe 25 (OH) vit. D levels had a significant p-value (p < 0.001) (Table 2). Comparison of vit. D levels according to the mMRC scale at different grades had a significant p-value (p < 0.001) (Table 3). Comparison of mean values of vit D in the 6-minute walk test (6 MMT) in different meters had a significant p-value (p < 0.001) (Table 4). In comparison of ICS in usage and non-usage of patients, there was a significant p-value (p < 0.001) (Table 5). These findings are more or less in agreement with previous studies.^[5,6,7]

Patients with COPD are at high risk of being vitamin D deficient due to a variety of reasons: aging skin is less effective in producing vitamin D, poor nutrition and outdoor activities, increased catabolism of vitamin D by steroids, and lower storage capacity.^[8] The normal functioning of both innate and adaptive immunity is dependent on vit-D, such as the maturities of dendritic cells, negative regulation of pro-inflammatory cytokines and chemokines, and maturation and development of T cells, especially Th1 cells.^[9] Vitamin D is also linked to apoptosis and intracellular adhesions. Increased expression of antimicrobial peptides such as cathelicidin and beta defensins is an important function of vit D to maintain homeostasis.^[10] Immune cells both have a vitamin D receptor (VDR) and a hydroxylase enzyme and can potentially reduce the pathogenic load of micro-organisms. Vit. D in airway epithelium helps to kill pathogens via TLS and CD 14-dependent mechanisms. The vitamin D receptor (VDR) is an important nuclear hormone receptor, and animal studies have confirmed that VDR has observed lung changes. Similar to COPD and chronic respiratory failure, increased inflammation and up-regulation of various matrix metalloproteinases (MMPs),^[11] lead to early-onset emphysema and decline in lung functions. Higher exercise capacity and carbon monoxide transfer capacity were associated with higher levels of vitamin D levels.^[12].

CONCLUSION

Present study of vitamin D status in COPD. It is observed that vitamin D level is significantly decreased in COPD patients. Such studies must be conducted in a large number of patients in hi-tech respiratory research centers to confirm present significant results because the exact mechanism of vit. D in respiratory units like respiratory bronchioles, alveoli, and surfactant cells remains unclear.

Limitation of study: Owing to the tertiary location of the research center, a small number of patients lack the latest techniques, and we have limited findings and results.

- This research work was approved by the ethical committee of Gandhi Medical College, Secunderabad, Telangana-500003.
- No Conflict of Interest
- \triangleright Self-funding.

REFERENCES

- Soriano JB, Kendrick PJ: Prevalence and attributable health burden of chronic respiratory diseases Lancet Rest. Med. 2020, 8; 585-96.
- Khan DM, Ullah A: Role of vitamin D in reducing number of acute exacerbation of chronic obstructive pulmonary disease patients Pak. J. Med. Sc. 2017, 33; 610-4.
- Jindal SK, Agarwal AN: Multicentric study on the epidemiology of chronic obstructive pulmonary disease and its relation to tobacco smoking and environmental tobacco smoke exposure. Ind. J. of Chest D. Allied Science 2006, 48; 23-9.
- Burkes RM, Couper DJ, Barjaktarevic IZ, et al. Agedependent associations between 25-hydroxy vitamin D levels and COPD symptoms: analysis of SPIROMICS. Chronic ObstrPulm Dis. 2021;8(2):277-291. doi: https://doi.org/10.15326/jcopdf.2020.0180.
- Maes K, Serre J: Targeting vitamin D deficiency to limit exacerbation in respiratory diseases. Calcif. Tissue Int. 2020, 106 (1); 76-87.
- Gilbert CR, Arum SM: Vitamin D deficiency and chronic lung disease J. Can. Respir. 2009, 16 (3); 75-80.
- Shi Y, Liu T: Chronic vitamin deficiency induces lung fibrosis through activation of the renin-angiotensin system. J. Sc. Rep. 2017, 7 (1); 1-10.
- Mulrennan S, Knuiman M: Vitamin D and respiratory health in the Busselton Healthy Aging Study Respirology 2018, 23 (6); 576-82.
- Monadi M, Heidari B: Relationship between serum vitamin D and forced expiratory volume in patients with COPD Caspian J. intern Med. 2012, 3; 451-5.
- Forli L Halse J: Vitamin D deficiency, bone mineral density, and weight in patients with advanced pulmonary disease J. Int. Med. 2004, 256; 56-62.
- Finklea JD, Grossman RE: Vitamin D and chronic lung disease Advance Nutrition 2011, 2; 244-53.
- Rafiq R, Thijs W: Association of serum 25 (OH) D concentration with lung function, airway inflammation J. Nutrition 2018, 31 (2); 38-42.